Cardiac Hemochromatosis

Cardiac hemochromatosis is a genuinely distinctive entry in this section’s storage and infiltrative disease group, precisely because it breaks the pattern the others establish: there’s no characteristic hypertrophy to look for, and the single most important imaging test for catching it early isn’t echocardiography at all.

What Cardiac Hemochromatosis Is

Hemochromatosis is a systemic disorder of abnormal iron accumulation affecting multiple organs — the liver, pancreas, joints, pituitary gland, and heart. It arises through two genuinely different mechanisms worth distinguishing:

• Primary (hereditary) hemochromatosis — most commonly an autosomal recessive condition from two point mutations on chromosome 6, C282Y and H63D, causing excessive intestinal iron absorption.
• Secondary iron overload — from increased dietary iron intake, chronic blood transfusions (as in hereditary anemias requiring repeated transfusion), or the increased intestinal iron absorption seen in chronic liver failure.

Both routes converge on the same cardiac consequence: progressive iron deposition in the myocardium. Symptom onset is genuinely variable, with first symptoms reported anywhere between ages 15 and 80. Cardiac involvement is frequently recognized only after extracardiac manifestations have already prompted the systemic diagnosis — liver disease, joint symptoms, diabetes (from pancreatic involvement), and the classic skin hyperpigmentation that gives the condition its old nickname of “bronze diabetes,” which remains a genuine, actively useful physical exam clue pointing toward this diagnosis specifically.

The Key Structural Point: Wall Thickness Is Typically Not Increased

This is worth stating as the organizing fact for the whole page, since it’s what genuinely separates hemochromatosis from the other storage and infiltrative diseases covered elsewhere in this section: in its functional, echo-detectable form, LV wall thickness is typically not increased. Unlike cardiac amyloidosis, Fabry disease, or glycogen storage disease — all of which are built around some pattern of increased wall thickness — iron deposition in hemochromatosis tends to produce its effects on cardiac function well before, or sometimes entirely without, the structural hypertrophy those other conditions are organized around. Cardiac hypertrophy can be seen in some patients, particularly in early disease, but it isn’t the dominant or expected finding the way it is in amyloidosis or Fabry disease — the real story in hemochromatosis is functional, not structural.

Three Distinct Disease Patterns — Not One Fixed Trajectory

Rather than a single, linear progression, hemochromatosis can present as any of three genuinely different pictures, and recognizing which one a given patient has matters for interpretation:

1. Early disease: isolated diastolic dysfunction with structurally normal walls — often presenting simply as unexplained dyspnea, with echo otherwise looking unremarkable by conventional measures.
2. Most commonly, as disease progresses: a dilated cardiomyopathy phenotype, with severe heart failure — see Dilated Cardiomyopathy for the general assessment framework this presentation falls into. Hemochromatosis is grouped alongside cardiac sarcoidosis and amyloidosis as an infiltrative cause capable of producing this same dilated phenocopy.
3. Uncommonly: a restrictive phenotype instead — preserved ejection fraction, severe diastolic dysfunction, and pulmonary hypertension — see Restrictive Cardiomyopathy for the broader framework this rarer presentation fits into.

Conduction system involvement is a genuine, separate feature worth screening for specifically — hemochromatosis can produce varying degrees of heart block through direct iron deposition in the conduction system, independent of which of the three ventricular patterns above a given patient shows.

Echocardiographic Findings

• Myocardial speckling can be seen in overt disease, though — as with the “granular sparkling” sign discussed on the amyloidosis page — this finding is nonspecific and shouldn’t be relied upon as a primary diagnostic marker on its own.
• Diastolic dysfunction, assessed by the standard approach — see LV Diastolic Function for the general framework — is frequently the earliest detectable echo abnormality, often present before any structural or systolic change is apparent.
• Speckle-tracking strain — longitudinal strain and torsion specifically — can reveal abnormal myocardial mechanics even when the heart appears entirely normal by conventional structural and functional measures. This is a genuinely useful early-detection application: strain imaging can flag disease before diastolic dysfunction itself becomes apparent on standard Doppler assessment, in a heart that otherwise looks unremarkable.
• As the three-pattern framework above indicates, later findings depend on which phenotype predominates — chamber dilation with reduced EF in the more common dilated pattern, or marked biatrial enlargement with preserved EF and a restrictive filling pattern in the less common restrictive presentation.
• RV involvement and pulmonary hypertension can accompany the restrictive presentation specifically — see Evaluation of the Right Ventricle for the standard assessment approach.

Why Cardiac MRI — Not Echo — Is the Real Diagnostic Tool

This is worth stating plainly: the earliest, most clinically actionable detection of cardiac iron overload comes from cardiac MRI, specifically T2 mapping — not from echocardiography.* T2* sequences directly quantify myocardial iron deposition, and a shortened T2* value is the defining tissue-characterization finding for cardiac hemochromatosis, distinguishing it from the LGE-based patterns used to characterize most of the other infiltrative and storage conditions in this section.

This distinction matters clinically, not just technically: there’s genuine evidence that phlebotomy or chelation therapy started early — guided by CMR detection of iron overload before overt functional decline — can reverse the disease process. Echo’s findings (diastolic dysfunction, then evolution toward DCM or, less commonly, RCM) typically only become apparent once the underlying process is already well underway. In practice, this means echocardiography’s genuine value here is in monitoring functional consequences and disease progression, while CMR is what actually catches the disease early enough for treatment to meaningfully change its course.

A second, genuinely practical application of T2 CMR worth knowing*: screening patients scheduled for liver transplantation, where undetected cardiac iron overload carries real perioperative risk — a reminder that this test’s value extends beyond cardiology into broader perioperative planning for a systemic disease.

Diagnosis is typically confirmed by combining serological evidence of iron overload with T2-weighted imaging findings in both the heart and liver on CMR, and tissue diagnosis when needed.

How to Diagnose It: A Practical Sequence

1. Consider the systemic context first — known hereditary hemochromatosis, a history of chronic transfusion, chronic liver disease, or the classic skin hyperpigmentation should all raise suspicion, especially in a patient with otherwise unexplained heart failure or diastolic dysfunction.
2. Don’t expect increased wall thickness — unlike the other storage and infiltrative diseases in this section, a structurally unremarkable heart doesn’t argue against the diagnosis.
3. Assess diastolic function carefully, since this is frequently the earliest echo-detectable abnormality, and consider speckle-tracking strain (longitudinal strain and torsion) even when conventional parameters look normal, given its value for detecting subclinical disease.
4. Determine which of the three patterns is present — isolated diastolic dysfunction, a dilated phenotype (the most common evolution), or the less common restrictive phenotype with preserved EF and pulmonary hypertension — since this shapes both the differential and the monitoring plan going forward.
5. Screen for conduction system involvement on ECG alongside the echo, given its frequency and independence from the ventricular phenotype.
6. When hemochromatosis is genuinely suspected, recommend cardiac MRI with T2 mapping* — this is the test that actually detects iron overload early enough to matter, rather than relying on echo findings that typically appear only once disease is already established.
7. If cardiac iron overload is confirmed, recognize that early initiation of phlebotomy or chelation therapy has genuine potential to reverse the process — a reason urgency in diagnosis translates directly into treatment benefit here, more so than in many of the other conditions covered in this section.

Clinical Importance

Cardiac hemochromatosis is the clearest example in this section of a condition where echocardiography’s role is genuinely secondary to another imaging modality — not because echo is inadequate, but because the disease’s own biology means the window for disease-modifying treatment closes before most of echo’s findings have had a chance to appear. The practical lesson is to use echo for what it does well here (diastolic function, strain, and longitudinal monitoring of whichever phenotype develops) while recognizing that T2* CMR, not a repeat echocardiogram, is what should be reached for when the diagnosis is genuinely on the table and early treatment is still a realistic goal.